Headlines

© GettyImages/Frank Brennan

ADDF: Anti-amyloids are a promising starting point

The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference demonstrate why optimal treatment of Alzheimer’s will require drugs that do more than clear amyloid plaques, says the Alzheimer’s Drug Discovery Foundation (ADDF).

Global Industry News

Hot Topics

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers